Table of Contents :
• Stock Rating & Target Price
• Investment Thesis
• Fundamental Models Used
• Company Description
• Corporate Timeline
• Key Metrics (KPI ) and Recently Reported Earnings Review
• Business Highlights, Strategic Announcements & Outlook
• Quarter-over-Quarter (Q-o-Q) and Year-over-Year (Y-o-Y) Growth Analysis
• Key Catalysts Driving Growth
• Historical Financial Statement Analysis & CAGR Trends
• Quarterly Key Financial Ratios and Performance Metrics
• Annual Financial Performance Analysis: Horizontal and Vertical Financial Analysis, Trends
• Financial Forecasts
• Annual Forecasts: Income Statement
• Annual Forecasts: Cash Flow Statements
• Net Debt Levels
• A Closer Look at DCF: Our Assumptions and Methodology
• Terminal Value Calculation
• Target Price Analysis
• Valuation Multiples
• Supplementary Valuation Analysis: Multiples Approach
• Scenario/Sensitivity Analysis – Base Case , Bull Case ,Bear Case
• Holistic Peer Review & Trading Comps: Financial Data, Operational Metrics, and Valuation Multiples
• Implied Price Per Share
• Ownership Activity/ Insider Trades
• Ownership Summary
• An analysis of ESG Risk Rating
• Key Professionals
• Key Board Members
• Key Risks Considerations
• Analyst Ratings
• Analyst Industry Views
• Disclosures
Pfizer’s High-Stakes Power Play: Election Win Shake-Up & Billion-Dollar Bet on China—What’s the Impact, Outlook, and Its Key Catalysts?
Pfizer’s Q3 2024 results highlight a robust operational performance with $17.7 billion in revenue, reflecting a 32% operational growth year-over-year, driven by a 14% rise in non-COVID sales. Key growth drivers include oncology (+31% y/y), supported by XTANDI and TALZENNA, alongside Seagen assets generating $854 million. Vaccines delivered strong gains, with Prevnar 20 commanding 97% U.S. market share and ABRYSVO achieving 43% retail market share. COVID revenues of $4.1 billion signal stabilization, with Pfizer raising full-year COVID guidance to $10.5 billion. Adjusted EPS of $1.06 exceeded expectations, demonstrating disciplined cost management and a favorable tax mix. Pipeline momentum includes obesity treatments, trispecific antibodies, and innovative oncology assets. Strategic initiatives, such as the "China 2030 Strategy," position Pfizer to capitalize on aging demographics, despite risks from IRA pricing pressures and competition in RSV and autoimmune markets. Adjusted full-year revenue guidance increased to $61-64 billion with 9-11% non-COVID growth, bolstered by cost optimization and expanded product penetration. However, geopolitical uncertainties, competitive dynamics, and regulatory risks under a Trump presidency present challenges. As Pfizer bets big on China and faces shifting U.S. policy dynamics, how effectively can it balance these opportunities and risks to sustain its leadership in high-value, high-margin markets?
